Stock analysts at StockNews.com started coverage on shares of Spectrum Pharmaceuticals (NASDAQ:SPPI – Get Rating) in a research note issued to investors on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Other equities analysts have also issued reports about the stock. JMP Securities restated a “buy” rating and set a $4.00 price target on shares of Spectrum Pharmaceuticals in a research report on Friday, September 23rd. HC Wainwright decreased their target price on shares of Spectrum Pharmaceuticals from $12.00 to $9.00 and set a “buy” rating on the stock in a report on Tuesday, September 20th. Finally, B. Riley lowered shares of Spectrum Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the company from $1.50 to $1.00 in a report on Wednesday, November 16th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $4.67.
Spectrum Pharmaceuticals Trading Down 2.8 %
SPPI opened at $0.44 on Monday. The firm has a market capitalization of $82.30 million, a PE ratio of -0.68 and a beta of 2.04. Spectrum Pharmaceuticals has a twelve month low of $0.36 and a twelve month high of $1.81. The firm’s 50-day moving average price is $0.53 and its 200 day moving average price is $0.79.
Hedge Funds Weigh In On Spectrum Pharmaceuticals
Spectrum Pharmaceuticals Company Profile
Spectrum Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma.
- Get a free copy of the StockNews.com research report on Spectrum Pharmaceuticals (SPPI)
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.